

REMARKS

This supplemental response is filed solely to cancel 23-26 and 34-39 per the Examiners telephone request on December 11, 2008.


Claim 22 is pending in the application. Claims 1 – 21, 23-26, and 34-39 have been cancelled.

The Examiner has indicated that the instant compounds directed to the elected group (claim 22) are allowable over the prior art with the cancellation of the above-mentioned cancelled claims.

Reconsideration and allowance of the application in view of the amendments to the claims and remarks is earnestly solicited.

The Commissioner is hereby authorized to charge any fees required or credit any overpayment to Deposit Account No. 07-1392.

Respectfully submitted,


Bonnie L. Deppenbrock
Attorney for Applicant
Registration No. 28,209

Date: 11 December 2008
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-1577
Facsimile: 919-483-7988